Aeglea BioTherapeutics

General Information

We are a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism that we believe will transform the lives of patients with inborn errors of metabolism and cancer. Our engineered human enzymes are designed to degrade specific amino acids in the blood. In inborn errors of metabolism, or IEM, a subset of rare genetic metabolic diseases, we are seeking to reduce the toxic levels of amino acids in patients. In oncology, we are seeking to reduce amino acid blood levels below the normal range where we believe we will be able to exploit the dependence of certain cancers on specific amino acids. Our lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers which have been shown to have a metabolic dependence on arginine. AEB1102 has demonstrated the ability to reduce blood arginine levels in nonclinical studies, supporting its potential use as a treatment of both Arginase I deficiency and cancer.

Employees: 23
Founded: 2013
Contact Information
Address 901 S. MoPac Expressway, Barton Oaks Plaza One, Suite 250, Austin, TX 78746, US
Phone Number (512) 942-2935
Web Address
View Prospectus: Aeglea BioTherapeutics
Financial Information
Market Cap $129.3mil
Revenues $6.1 mil (last 12 months)
Net Income $-11.5 mil (last 12 months)
IPO Profile
Symbol AGLE
Exchange NASDAQ
Shares (millions): 5.0
Price range $10.00 - $10.00
Est. $ Volume $50.0 mil
Manager / Joint Managers UBS Investment Bank/ BMO Capital Markets/ Wells Fargo Securities
CO-Managers Needham & Company
Expected To Trade: 4/7/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change